PTAB issues first written decisions on biopharmaceutical IPRs

The Patent Trial and Appeal Board has invalidated a set of patents covering an enzyme replacement therapy
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: